PharmaVOICE - 
February 2014
Purchase Issue

In Every Issue
Last Word
Biopharmaceutical companies are becoming more fully ­engaged with patients as [...]
By

Tom Sellers, Head of Patient Advocacy, Millennium

Talent Pool
Pharma Pool Dr. Yong-Jun LIU Medimmune Names New Head of [...]
By

Ann Grey

On the Calendar
The Calendar Industry Events and Conferences, including special discounts Coming [...]
By

Heather Hummel

PharmaTrax
Pipelines are Shifting to Biotech Drugs Trending Now: Large molecules [...]
By

Denise Myshko

Tools of the Trade
GSW Launches Multi-Channel Detailing Platform Trending Now: eDetailing allows for [...]
By

Denise Myshko

What’s New
CAHG and Diaceutics to Launch Bioceutics Trending Now: New agency [...]
By

Ann Grey

Social Buzz
Trending Now: Only 50% of companies have developed meaningful social [...]
By

Taren Grom, Editor

Innovator’s Corner
The Fly Boy Dr. Ross Cagan’s approach to drug discovery [...]
By

Dr. Ross Cagan, professor in the department of ­development and regenerative biology, and ­associate dean, graduate school of biological sciences at the Icahn School of Medicine at Mount Sina

UpFront
INDUSTRY at Large AbbVie Provides Grant for Math Education AbbVie [...]
By

Denise Myshko

Letter to the Editor
Jonah Frohlich Managing Director Manatt Health Solutions The ACA is [...]
By

Jonah Frohlich, Managing Director, Manatt Health Solutions

Letter from the Editor
The State of the Industry many companies are at a [...]
By

Taren Grom, Editor

On The Cover

Specialty Drugs: An Evolving Commercial Model
A changing marketplace creates new challenges and new business models for specialty medications. At the same time the industry is increasing its focus on developing specialty drugs — a projected 40% growth by 2014 and 67% by 2015, according to Express Scripts — the reimbursement, marketing, and sales landscape of these products is also increasing [...]
By

Robin Robinson

Features

Upping Their Game: CROs Must Develop A New Mindset to Partners with Sponsors
Contributed by: Mark Scullion, Senior VP, Strategic Resourcing, Inventiv Health Clinical As companies evaluate CRO partners, even for transactional work, they should be considering their potential fit for a more aligned relationship in the future. Forming an aligned partnership can lower costs, reduce oversight, and support the type of visionary goals that will deliver competitive [...]
By

Mark Scullion, Senior VP, Strategic Resourcing, Inventiv Health Clinical

Creating Sustainable Growth, Profitability, and Innovation
Balkrishan Kalra, Senior Vice President & Global Business Leader, Life Sciences, Genpact Can your business process operations support disruptive new strategies, and nontraditional business models? Today, the life sciences industry faces unprecedented challenges, uncertainty and risk that are unlikely to abate anytime soon. Most players are exploring a variety of organizational strategies to adapt to [...]
By

Balkrishan Kalra, Senior Vice President & Global Business Leader, Life Sciences, Genpact

SHOWCASE FEATURE: Outsourcing: Adding Value to the Model
SHOWCASE FEATURE: Outsourcing: Outsourcing: Adding Value to the Model By Tarem Grom, Editor Outsourcing has become a standard worldwide business practice and management imperative and stakeholders are looking for more than cost- savings. A relatively small number of BPO clients — 20% of those participating in Accenture’s research study — have succeeded in extracting greater [...]
By

Taren Grom, Editor

C-Suite: Biotechnology
Biotechnology C-suite executives identify the biggest opportunities for innovation as well as the biggest barriers. Lloyd Everson, M.D CEO MolecularHealth Opportunities: The greatest opportunity for innovation within the biotechnology space lies in the rapidly increasing amount of data furthering the complexity of cell biology, and the ability to use it for clinical action. Big data [...]
By

Taren Grom, Editor

Singapore a Pharma Hub for Asia
Singapore a Pharma Hub for Asia By Kim Ribbink The pharma industry is increasingly drawn to Singapore, thanks to its commitment to research and innovation, good talent base, and trusted regulatory and IP environment. Singapore is fast becoming a leading regional and even global center for the life-sciences industry. According to Datamonitor, Singapore was the [...]
By

Kim Ribbink

Global Regulations Becoming More Uniform
Pharmaceutical companies must navigate a changing regulatory environment both here and abroad. As the digital age brings the clinical world closer together and research and development become more global, the industry needs to find a way to address regulatory requirements across myriad regions. The global regulatory environment is getting more rigorous, and regulators around the [...]
By

Denise Myshko

Preparing for a Successful FDA Inspection
Pharmaceutical manufacturers need to be inspection ready, aligning their organization with the expectations of regulators. Preparing for successful inspections is not a one-time event. Being inspection ready means that pharmaceutical leaders are committed to managing compliance as part of their company culture. Industry experts say successfully managing compliance is something that is done every day [...]
By

Denise Myshko

Rare Diseases: The Patient as Collaborator
In the rare disease market, working with patients and patient advocacy groups is critical for the success of new therapies. The voice of the patient is critical in healthcare. Nowhere is this more true than in the area of rare diseases. It’s critical to engage patients, industry experts say, to access the knowledge that patients [...]
By

Denise Myshko

App Revolution: Avoiding the App Trap
App Revolution: Avoiding the App Trap The industry needs to create valuable apps that fill an unmet need and rise above the deluge of online services now available. Pocket.md, a directory of mobile medical applications, lists more than 1,500 mobile apps that have been produced by biotechnology, pharmaceutical, and medical device companies. Out of those [...]
By

Robin Robinson

FEEDBACK